{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:07:11Z","timestamp":1794708431418,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Treatment-free remission is one of the most important goals of CML treatment but so far, the best treatment to reach this aim is still undefined, even though it is widely accepted that a sustained DMR is the prerequisite to discontinue TKI. Here we report on the depth of the molecular response, the first co-primary end point of the SUSTRENIM study, in a cohort of newly diagnosed CP-CML patients randomized 1:1 to be treated with nilotinib or with imatinib followed by switching to nilotinib in absence of optimal response. Of the 448 enrolled patients, 228 and 220 were randomized to the nilotinib (NIL) and imatinib (IM) arms, respectively, and followed for a median of 45.9 months. Eighty-two (37.2%) of the 220 patients on the IMarm did not fulfill the ELN criteria for optimal response of treatment and switched to nilotinib therapy. At the 24 months of follow-up, 107 of the 448 patients reached an MR4.5 response with a significantly higher frequency within the patients on the nilotinib arm (65 vs 42;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). The analysis of the first primary endpoint indicates that, despite the early switch in the IM-randomized patients, NIL therapy is more effective to induce DMR.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02796-z","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T10:31:22Z","timestamp":1763461882000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-2628","authenticated-orcid":false,"given":"Fausto","family":"Castagnetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-2894","authenticated-orcid":false,"given":"Renato","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-1686","authenticated-orcid":false,"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-5187","authenticated-orcid":false,"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-6878","authenticated-orcid":false,"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4737-4451","authenticated-orcid":false,"given":"Francesco","family":"Muriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Paoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Russo Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-3514","authenticated-orcid":false,"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-3465","authenticated-orcid":false,"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-7039","authenticated-orcid":false,"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"2796_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2796_CR2","doi-asserted-by":"crossref","unstructured":"Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019;3:4280\u201390.","DOI":"10.1182\/bloodadvances.2019000865"},{"key":"2796_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic myeloid leukemia, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2024;22:43\u201369.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2796_CR4","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","volume":"126","author":"RA Larson","year":"2015","unstructured":"Larson RA. Is there a best TKI for chronic phase CML? Blood. 2015;126:2370\u20135.","journal-title":"Blood"},{"key":"2796_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.24249","volume":"91","author":"E Jabbour","year":"2016","unstructured":"Jabbour E. Chronic myeloid leukemia: first-line drug of choice. Am J Hematol. 2016;91:59\u201366.","journal-title":"Am J Hematol"},{"key":"2796_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense. Blood Cancer J. 2023;13:58.","journal-title":"Blood Cancer J"},{"key":"2796_CR7","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024;42:1875\u201380.","journal-title":"J Clin Oncol"},{"key":"2796_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"2796_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Larson S, Saussele S, Rea D, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61:650\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2796_CR10","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3324\/haematol.2021.280175","volume":"107","author":"G Gugliotta","year":"2022","unstructured":"Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D\u2019Adda M, et al. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. Haematologica. 2022;107:2356\u201364.","journal-title":"Haematologica"},{"key":"2796_CR11","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","volume":"35","author":"JP Radich","year":"2021","unstructured":"Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35:1344\u201355.","journal-title":"Leukemia"},{"key":"2796_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ajh.26550","volume":"97","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022;97:856\u201364.","journal-title":"Am J Hematol"},{"key":"2796_CR13","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2796_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2796_CR15","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36:1825\u201333.","journal-title":"Leukemia"},{"key":"2796_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.leukres.2016.06.010","volume":"48","author":"M Breccia","year":"2016","unstructured":"Breccia M, Molica M, Colafigli G, Massaro F, Alimena G. Early molecular response in chronic myeloid leukemia and halving time: latest evidences. Leuk Res. 2016;48:20\u20135.","journal-title":"Leuk Res"},{"key":"2796_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11899-017-0375-0","volume":"12","author":"P Harrington","year":"2017","unstructured":"Harrington P, Kizilors A, de Lavallade H. The role of early molecular response in the management of chronic phase CML. Curr Hematol Malig Rep. 2017;12:79\u201384.","journal-title":"Curr Hematol Malig Rep"},{"key":"2796_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:71\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"2796_CR19","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/onco.13944","volume":"26","author":"MT Chen","year":"2021","unstructured":"Chen MT, Huang ST, Lin CW, Ko BS, Chen WJ, Huang HH, et al. Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population-based, propensity score-matched cohort study. Oncologist. 2021;26:974\u201382.","journal-title":"Oncologist"},{"key":"2796_CR20","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White HE, M\u00fcller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172\u20135.","journal-title":"Leukemia"},{"key":"2796_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2796_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30:48\u201356.","journal-title":"Leukemia"},{"key":"2796_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 2015;125:915\u201323.","journal-title":"Blood"},{"key":"2796_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02796-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02796-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:04:54Z","timestamp":1767985494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02796-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2796"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02796-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FC:\n                      Pfizer\n                      : Consultancy, Honoraria, Research Funding;\n                      BMS\n                      : Honoraria;\n                      Incyte\n                      : Consultancy, Honoraria;\n                      Novartis\n                      : Consultancy, Honoraria, Research Funding. MB:\n                      AOP\n                      ,\n                      Pfizer, BMS, Incyte\n                      ,\n                      AbbVie\n                      ,\n                      Novartis\n                      : Honoraria. EA:\n                      BMS\n                      : Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Incyte\n                      : Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Novartis\n                      : Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Pfizer\n                      : Consultancy;\n                      Takeda\n                      : Consultancy. GB:\n                      Novartis\n                      ,\n                      AOP, BMS\n                      ,\n                      Incyte\n                      ,\n                      GSK\n                      : Honoraria. MB: Amgen,\n                      Ascentage Pharma, Blueprint Medicines, BMS, GSK, Incyte, Novartis\n                      , Pfizer: Honoraria\/Adv board. F.C.:\n                      Novartis\n                      : Honoraria;\n                      Incyte\n                      : Honoraria;\n                      Pfizer\n                      : Honoraria. AI: AOP, Pfizer,\n                      BMS, Incyte\n                      ,\n                      Abb\n                      Vie, Novartis, GSK: Honoraria. JJWMJ:\n                      Novartis\n                      : Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      BMS\n                      : Other, Research Funding;\n                      Amgen\n                      : Other;\n                      Astellas\n                      : Other;\n                      Daiichi-Sankyo\n                      : Other;\n                      Janssen\n                      : Other;\n                      Olympus\n                      : Other;\n                      Incyte\n                      : Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other;\n                      Sanofi Gemzyme\n                      : Other;\n                      Servier\n                      : Other;\n                      Jazz\n                      : Other;\n                      Takeda\n                      : Other;\n                      Abbvie\n                      : Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Pfizer\n                      : Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees. RM:\n                      Abbvie, Janssen, Astra Zeneca\n                      : Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding, Speakers Bureau. GR:\n                      Novartis\n                      ,\n                      Incyte, Pfizer\n                      : Other, Speakers Bureau. SSo:\n                      Incyte, Novartis\n                      : Consultancy, Honoraria. PEW:\n                      Pfizer\n                      ,\n                      Novartis\n                      , Incyte,\n                      Bristol Myers Squibb- Celgene\n                      : Honoraria. FP:\n                      Incyte\n                      : Honoraria, Speakers Bureau;\n                      BMS\n                      : Speakers Bureau;\n                      Novartis\n                      : Honoraria, Speakers Bureau;\n                      Pfizer\n                      : Speakers Bureau. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study (\n                      \n                      NCT02602314) was approved by Ethics Committee \u201cUniversit\u00e0 Federico II\u201d, with the reference number 121_13_ES5. The study is being conducted in accordance with the Declaration of Helsinki and the International Councilfor Harmonisation Harmonized Tripartite Guidelines for GCP. The participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}